EBITA margin and profit improved significantly, with strong organic growth and cost control driving a 164% increase in profit before tax year-over-year. Net debt/EBITDA fell to 2.9, and both Labtech and Medtech segments saw margin gains and healthy demand.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.